Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6ZS82
UPID:
R9BP_HUMAN
Alternative names:
RGS9-anchoring protein
Alternative UPACC:
Q6ZS82; Q6ZVJ6
Background:
Regulator of G-protein signaling 9-binding protein (RGS9BP) is pivotal in GPCR signaling in phototransduction. It aids in the visual transduction recovery phase through interaction with RGS9-1, facilitating G protein GTPase activity for timely signal termination. RGS9BP serves as a membrane-anchor for RGS9-1 in photoreceptor outer segments, crucial for vision, and enhances RGS9-1's proteolytic stability.
Therapeutic significance:
RGS9BP's involvement in Prolonged electroretinal response suppression 2, an ocular disorder impairing adaptation to luminance changes, underscores its therapeutic potential. Understanding RGS9BP's role could unveil new strategies for treating phototransduction-related disorders.